202 related articles for article (PubMed ID: 32692448)
1. Head to head: should the intraductal component of invasive prostate cancer be graded?
Varma M; Epstein JI
Histopathology; 2021 Jan; 78(2):231-239. PubMed ID: 32692448
[TBL] [Abstract][Full Text] [Related]
2. Intraductal Carcinoma of the Prostate: A Guide for the Practicing Pathologist.
Varma M
Adv Anat Pathol; 2021 Jul; 28(4):276-287. PubMed ID: 33990497
[TBL] [Abstract][Full Text] [Related]
3. Grading of prostate cancer: the impact of including intraductal carcinoma on the overall Grade Group assigned in diagnostic biopsies.
Chen-Maxwell D; Prendeville S
Histopathology; 2020 Sep; 77(3):503-507. PubMed ID: 32358793
[TBL] [Abstract][Full Text] [Related]
4. Intraductal carcinoma of the prostate: a critical re-appraisal.
Varma M; Delahunt B; Egevad L; Samaratunga H; Kristiansen G
Virchows Arch; 2019 May; 474(5):525-534. PubMed ID: 30825003
[TBL] [Abstract][Full Text] [Related]
5. Grading Intraductal Carcinoma of the Prostate; ISUP versus GUPS Recommendations.
Shahid A; Mushtaq S; Maqbool H; Hassan U; Hussain M; Syed M
J Coll Physicians Surg Pak; 2023 Apr; 33(4):396-399. PubMed ID: 37190710
[TBL] [Abstract][Full Text] [Related]
6. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
[TBL] [Abstract][Full Text] [Related]
7. Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations.
Egevad L; Delahunt B; Kristiansen G; Samaratunga H; Varma M
Pathology; 2018 Jan; 50(1):60-73. PubMed ID: 29199015
[TBL] [Abstract][Full Text] [Related]
8. Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded.
Samaratunga H; Delahunt B; Egevad L; Srigley JR; Billis A; Bostwick DG; Camparo P; Cheng L; Clouston D; Denham J; Furusato B; Hartmann A; Jufe L; Kench J; Kenwright DN; Kristiansen G; Leite KRM; MacLennan GT; Merrimen J; Moch H; Oxley J; Pan CC; Paner G; Ro J; Sesterhenn IAM; Shanks J; Thunders M; Tsuzuki T; Wheeler T; Yaxley JW; Varma M
Pathology; 2020 Feb; 52(2):192-196. PubMed ID: 31843189
[TBL] [Abstract][Full Text] [Related]
9. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
10. Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation.
Srigley JR; Delahunt B; Samaratunga H; Billis A; Cheng L; Clouston D; Evans A; Furusato B; Kench J; Leite K; MacLennan G; Moch H; Pan CC; Rioux-Leclercq N; Ro J; Shanks J; Shen S; Tsuzuki T; Varma M; Wheeler T; Yaxley J; Egevad L
Pathology; 2019 Aug; 51(5):463-473. PubMed ID: 31279442
[TBL] [Abstract][Full Text] [Related]
11. Isolated Intraductal Carcinoma of the Prostate in Prostatectomy Specimens: Report of 2 Cases and Review of the Literature.
Grypari IM; Logotheti S; Lazaris AC; Kallidonis P; Fokaefs E; Melachrinou M; Zolota V; Tzelepi V
Int J Surg Pathol; 2020 Dec; 28(8):918-924. PubMed ID: 32456482
[TBL] [Abstract][Full Text] [Related]
12. Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread.
Sorvina A; Martini C; Prabhakaran S; Logan JM; S-Y Ung B; Moore C; Johnson IRD; Lazniewska J; Tewari P; Malone V; Brooks RD; Hickey SM; Caruso MC; Klebe S; Karageorgos L; O'Leary JJ; Delahunt B; Samaratunga H; Brooks DA
Pathology; 2023 Oct; 55(6):792-799. PubMed ID: 37422404
[TBL] [Abstract][Full Text] [Related]
13. Evolution, controversies and the future of prostate cancer grading.
Egevad L; Delahunt B; Yaxley J; Samaratunga H
Pathol Int; 2019 Feb; 69(2):55-66. PubMed ID: 30694570
[TBL] [Abstract][Full Text] [Related]
14. Intraductal Carcinoma of the Prostate: To Grade or Not to Grade.
Surintrspanont J; Zhou M
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001579
[TBL] [Abstract][Full Text] [Related]
15. The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - a matched-pair analysis.
Berg KD; Thomsen FB; Nerstrøm C; Røder MA; Iversen P; Toft BG; Vainer B; Brasso K
BJU Int; 2016 Jun; 117(6):883-9. PubMed ID: 26823232
[TBL] [Abstract][Full Text] [Related]
16. Grade group 4 prostate cancer without intraductal carcinoma on biopsy is more likely to be downgraded on prostatectomy than with intraductal carcinoma.
Trabzonlu L; Chaiprasit T; Kontosis A; Picken M
Virchows Arch; 2024 Mar; 484(3):517-520. PubMed ID: 38267757
[TBL] [Abstract][Full Text] [Related]
17. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
Epstein JI; Amin MB; Reuter VE; Humphrey PA
Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
[TBL] [Abstract][Full Text] [Related]
18. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Epstein JI; Egevad L; Amin MB; Delahunt B; Srigley JR; Humphrey PA;
Am J Surg Pathol; 2016 Feb; 40(2):244-52. PubMed ID: 26492179
[TBL] [Abstract][Full Text] [Related]
19. International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading.
Egevad L; Delahunt B; Srigley JR; Samaratunga H
APMIS; 2016 Jun; 124(6):433-5. PubMed ID: 27150257
[TBL] [Abstract][Full Text] [Related]
20. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
